(UroToday.com) Dr. Tobias Nordstrom presented on the Stockholm3 MRI trial, which is a risk-adapted screening protocol incorporating genomics and MRI. The aim of this study was to compare traditional screening with web-based risk prediction combined with MRI-targeted biopsies for prostate cancer screening. This was a population-based screening-by-invitation noninferiority trial. The trial flow diagram is listed below.